BTIG Research Reiterates Buy Rating for Solventum (NYSE:SOLV)

Posted by Don Miller on Feb 27th, 2026

Solventum (NYSE:SOLV – Get Free Report)‘s stock had its “buy” rating restated by analysts at BTIG Research in a report issued on Friday,Benzinga reports. They presently have a $100.00 price target on the stock. BTIG Research’s target price suggests a potential upside of 29.45% from the stock’s current price.

SOLV has been the subject of several other reports. Stifel Nicolaus upped their target price on Solventum from $88.00 to $105.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. UBS Group reiterated a “neutral” rating on shares of Solventum in a report on Friday, November 21st. KeyCorp raised Solventum from a “sector weight” rating to an “overweight” rating and set a $97.00 price target on the stock in a research report on Monday, January 26th. Mizuho set a $100.00 price objective on shares of Solventum and gave the company an “outperform” rating in a research report on Tuesday, January 20th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Solventum in a report on Tuesday, January 27th. Seven equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Solventum presently has an average rating of “Hold” and an average target price of $91.36.

View Our Latest Report on Solventum

Solventum Stock Up 2.9%

SOLV stock opened at $77.25 on Friday. The stock has a market cap of $13.40 billion, a P/E ratio of 8.90, a PEG ratio of 6.90 and a beta of 0.35. The company has a quick ratio of 1.14, a current ratio of 1.50 and a debt-to-equity ratio of 1.03. The business’s 50-day moving average price is $78.73 and its 200-day moving average price is $76.19. Solventum has a twelve month low of $60.70 and a twelve month high of $88.20.

Solventum (NYSE:SOLV – Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $1.50 by $0.07. The business had revenue of $2 billion for the quarter, compared to the consensus estimate of $1.96 billion. Solventum had a return on equity of 28.01% and a net margin of 18.13%.The business’s revenue was down 3.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.41 earnings per share. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. On average, equities research analysts forecast that Solventum will post 6.58 EPS for the current year.

Solventum declared that its board has initiated a stock buyback plan on Thursday, November 20th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the company to purchase up to 7.5% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of SOLV. Hilltop National Bank raised its holdings in shares of Solventum by 71.3% during the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after acquiring an additional 129 shares during the last quarter. CrossGen Wealth LLC purchased a new stake in shares of Solventum during the fourth quarter worth approximately $25,000. Measured Wealth Private Client Group LLC acquired a new position in Solventum in the 3rd quarter valued at $25,000. JNBA Financial Advisors lifted its holdings in Solventum by 205.4% in the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after purchasing an additional 228 shares in the last quarter. Finally, CYBER HORNET ETFs LLC acquired a new stake in Solventum during the 2nd quarter worth $28,000.

Trending Headlines about Solventum

Here are the key news stories impacting Solventum this week:

Positive Sentiment: Q4 results topped estimates: Solventum reported $1.57 EPS vs. consensus $1.50 and $2.0B revenue vs. $1.96B, signaling solid underlying demand. Solventum beats quarterly estimates on strong demand for surgical products
Positive Sentiment: Management raised/guided FY2026: company set EPS guidance of $6.40–$6.60, above consensus, which supports the stock’s re‑rating on earnings visibility. Solventum Reports Fourth Quarter 2025 Financial Results and Introduces 2026 Full-Year Guidance
Positive Sentiment: End‑market strength in wound care and sterilization drove the beat and organic growth, suggesting durable product demand in core categories. Solventum exceeds earnings estimates in first year as solo company
Neutral Sentiment: Organic vs. reported sales split: organic sales rose ~3.5% but reported sales fell ~3.7% (impacted by the 3M spin‑off), so headline revenue comparisons are distorted. Solventum Reports Fourth Quarter 2025 Financial Results and Introduces 2026 Full-Year Guidance
Neutral Sentiment: Conference call/transcript available with management detail — useful for investors to judge sustainability of margin fixes and growth drivers. Solventum Corp (SOLV) Q4 2025 Earnings Call Highlights: Strong Organic Growth Amid Margin Challenges
Negative Sentiment: Margin pressures flagged on the call/notes — management acknowledged cost and mix headwinds that could limit near‑term margin expansion despite the beat. Solventum Corporation (SOLV) Q4 2025 Earnings Call Transcript
Negative Sentiment: Execution and comparability risk after the 3M spin‑off: analysts warn the new standalone setup creates an earnings test for future growth and margins. Solventum faces earnings test on growth targets after 3M spin-off

About Solventum

(Get Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.